Obesity and melanoma: Exploring molecular links

Journal of Cellular Biochemistry

Volumn 114, Issue 9, 2013, Pages 1955-1961

  Chen, Jiezhong ^a   Chi, Mengna ^b   Chen, Chen ^a   Zhang, Xu Dong ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

MAPK; MELANOMA; OBESITY; PI3K AKT; STAT3

Indexed keywords

ADIPONECTIN; EVEROLIMUS; INSULIN; INTERLEUKIN 17; INTERLEUKIN 6; LEPTIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; SOMATOMEDIN BINDING PROTEIN; STAT3 PROTEIN; STEM CELL FACTOR; TEMOZOLOMIDE; VASCULOTROPIN;

APOPTOSIS; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CHROMOSOME 10; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; IMMUNOSURVEILLANCE; INSULIN BLOOD LEVEL; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; METASTATIC MELANOMA; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ULTRAVIOLET RADIATION; VIRUS ONCOGENE;

EID: 84881383518     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24549     Document Type: Review

References (106)

1. Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A,. 2008. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18 (1): 29-35.
2. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M,. 2010. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17 (2): 351-360.
3. Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM,. 2010. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 16 (24): 6029-6039.
4. Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F,. 2009. The PI3K/Akt and mTOR/P70S6K signaling pathways in humanuveal melanoma cells: Interaction with B-Raf/ERK. Invest Ophthalmol Vis Sci 51 (1): 421-429.
5. Balmanno KCS,. 2009. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16 (3): 368-377.
6. Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A,. 2006. Molecularly targeted therapy for melanoma: Current reality and future options. Cancer 107 (10): 2317-2327.
7. Brandon EL, Gu JW, Cantwell L, He Z, Wallace G, Hall JE,. 2009. Obesity promotes melanoma tumor growth: Role of leptin. Cancer Biol Ther 8 (19): 1871-1879.
8. Calle EE, Kaaks R,. 2004. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (8): 579-591.
9. Chen J,. 2008. Is Src the key to understanding metastasis and developing new treatments for colon cancer ? Nat Clin Pract Gastroenterol Hepatol 5 (6): 306-307.
10. Chen J, Huang XF,. 2009. Interleukin-6 promotes carcinogenesis through multiple signal pathways. Dig Dis Sci. 54 (6): 1373-1374.
11. Chen J,. 2010. The Src/PI3K/Akt signal pathway may play a key role in decreased drug efficacy in obesity-associated cancer. J Cell Biochem 110 (2): 279-280.
12. Chen J,. 2011. Multiple signal pathways in obesity-associated cancer. Obesity Rev 12 (12): 1063-1070.
13. Chen J, Huang XF, Qiao L, Katsifis A,. 2011a. Insulin caused drug resistance to oxaliplatin in colon cancer cell HT29. J Gastrointest Oncol 2: 27-33.
14. Chen J, Katsifis A, Hu C, Huang XF,. 2011b. Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway. Curr Drug Discov Technol 8 (2): 119-125.
15. Chen J,. 2012a. Targeted therapy of obesity-associated colon cancer Transl Gastrointest Cancer 1 (1): 44-57.
16. Chen J,. 2012b. Prevention of obesity-associated colon cancer by (-)-epigallocatechin-3 gallate and curcumin. Transl Gastrointest Cancer 1: 44-57.
17. Chen J, McMillan NA,. 2008. Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. Cancer Biol Ther 7 (2): 174-179.
18. Chen J, Wang MB,. 2012. The roles of miRNA-143 in colon cancer and therapeutic implications. Transl Gastrointest Cancer 1 (2): 169-174.
19. Chen J, Huang XF, Katsifis A,. 2010. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem 111 (5): 1082-1086.
20. Cheung M, Sharma A, Madhunapantula SV, Robertson GP,. 2008. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68 (9): 3429-3439.
21. Chin L,. 2003. The genetics of malignant melanoma: Lessons from mouse and man. Nat Rev Cancer 3 (8): 559-570.
22. Chin L, Garraway LA, Fisher DE,. 2006. Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 20 (16): 2149-2182.
23. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA,. 2005. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37 (7): 745-749.
24. Courtney KD, Corcoran RB, Engelman JA,. 2010. The PI3K pathway as drug target in human cancer. J Clin Oncol 28 (6): 1075-1083.
25. Curtin JA, Busam K, Pinkel D, Bastian BC,. 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24 (26): 4340-4346.
26. Curtin JA, Kageshita FJ, Patel T, Busam HN, Kutzner KJ, Cho H, Aiba KH, Bröcker S, LeBoit EB, Pinkel PE, Bastian D, BC,. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med. 353 (20): 2135-2147.
27. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE,. 2009. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15 (24): 7538-7546.
28. Davies H, Cox BG, Stephens C, Edkins P, Clegg S, Teague S, Woffendin J, Garnett H, Bottomley MJ, Davis W, Dicks N, Ewing E, Floyd R, Gray Y, Hall K, Hawes S, Hughes R, Kosmidou J, Menzies V, Mould A, Parker C, Stevens A, Watt C, Hooper S, Wilson S, Jayatilake R, Gusterson H, Cooper BA, Shipley C, Hargrave J, Pritchard-Jones D, Maitland K, Chenevix-Trench N, Riggins G, Bigner GJ, Palmieri DD, Cossu G, Flanagan A, Nicholson A, Ho A, Leung JW, Yuen SY, Weber ST, Seigler BL, Darrow HF, Paterson TL, Marais H, Marshall R, Wooster CJ, Stratton R, Futreal MR, 2002. Mutations of the BRAF gene in human cancer. Nature 417 (6892): 949-954.
29. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ,. 2001. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 117 (6): 1483-1489.
30. Dennis LK, Lowe JB, Lynch CF, Alavanja MC,. 2008. Cutaneous melanoma and obesity in the agricultural health study. Ann Epidemiol 18 (3): 214-221.
31. Dhomen N, Marais R,. 2009. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23 (3): 529-545.
32. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H, de Bock CE, Hersey P, Zhang XD,. 2011. Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene. 30: 3716-3726.
33. Dronca RS, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, Moore TD, Marchello BT, Markovic SN,. 2013. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: A North Central Cancer Treatment Group Study, N0675. Am J Clin Oncol.
34. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R, McTiernan A,. 2010. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29 (1): 32-39.
35. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M,. 2011. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377 (9765): 557-567.
36. Gallagher EJ, LeRoith D,. 2010. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21 (10): 610-618.
37. Ghosh P, Chin L,. 2009. Genetics and genomics of melanoma. Expert Rev Dermatol 4 (2): 131.
38. Gislette T, Chen J,. 2010. The possible role of IL-17 in obesity-associated cancer. Sci World J 10: 2265-2271.
39. Gogas H,., Trakatelli M, Dessypris N, Terzidis A, Katsambas A, Chrousos GP, Petridou ET,. 2008. Melanoma risk in association with serum leptin levels and lifestyle parameters: A case-control study. Ann Oncol 19 (2): 384-389.
40. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA,. 2010. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70 (21): 8736-47.
41. Gu JW, Young E, Patterson SG, Makey KL, Wells J, Huang M, Tucker KB, Miele L,. 2011. Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice. Cancer Biol Ther 11 (10): 910-917.
42. Hanahan D, Weinberg RA,. 2011. Hallmarks of cancer: The next generation. Cell 144 (5): 646-674.
43. Hersey P, Zhang XD,. 2001. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 1 (2): 142-150.
44. Huang C-Y, Yu H-S, Lai T-Y, Yeh Y-L, Su C-C, Hsu H-H, Tsai F-J, Tsai C-H, Wu H-C, Tang C-H,. 2010. Leptin increases motility and integrin up-regulation in human prostate cancer cells. J Cell Physiol 226 (5): 1274-82.
45. Huang XF, Chen J,. 2009a. Obesity, the PI3K/Akt signal pathway and colon cancer. Obesity Rev 10 (6): 610-616.
46. Huang XF, Chen J,. 2009b. Adiponectin and signal pathways in obesity-induced colon cancer: Comment on "adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition." Gut 58 (8): 1169.
47. Ibrahim N, Haluska FG,. 2009. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 4: 551-579.
48. Jaffe T, Schwartz B,. 2008. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. J Int Cancer 123 (11): 2543-2556.
49. Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L,. 2011. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol 651 (1-3): 41-50.
50. Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN,. 2010. Integrative genome comparison of primary and metastatic melanomas. PLoS ONE 5 (5): e10770.
51. Kabbarah O, Chin L,. 2005. Revealing the genomic heterogeneity of melanoma. Cancer Cell 8 (6): 439-441.
52. Kannan K, Sharpless NE, Xu J, O'Hagan RC, Bosenberg M, Chin L,. 2003. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA 100 (3): 1221-1225.
53. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW,. 2008. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990. s. Eur J Cancer 44 (10): 1345-1389.
54. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, Pandolfi PP,. 2011. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147 (2): 382-395.
55. Kushiro K, Chu RA, Verma A, Nunez NP,. 2012. Adipocytes Promote B16BL6 Melanoma Cell Invasion and the Epithelial-to-Mesenchymal Transition. Cancer Microenviron 5 (1): 73-82.
56. Lavoie JN, L'Allemain RN, Pouysségur G, J,. 1996. A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res (2): 49-58.
57. Liang R, Wallace AR, Schadendorf D, Rubin BP,. 2011. The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma. Pigment Cell Melanoma Res
58. Madhunapantula SV, Robertson GP,. 2009. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 22 (4): 400-419.
59. Mantzoros CS, Trakatelli M, Gogas H, Dessypris N, Stratigos A, Chrousos GP, Petridou ET,. 2007. Circulating adiponectin levels in relation to melanoma: a case-control study. Eur J Cancer 43 (9): 1430-1436.
60. Mijovic T, How J, Payne RJ,. 2011. Obesity and thyroid cancer. Front Biosci (Schol Ed) 3: 555-564.
61. Ming M, He YY,. 2009. PTEN: New insights into its regulation and function in skin cancer. J Invest Dermatol 129 (9): 2109-2112.
62. Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD, DiGiovanni J,. 2008. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res (Phila) 1 (1): 65-76.
63. Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, Chin L, Kim M,. 2010. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29 (47): 6222-32.
64. Oh SW, Yoon YS, Shin SA,. 2005. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23 (21): 4742-4754.
65. O'Hagan RC, Brennan CW, Strahs A, Zhang X, Kannan K, Donovan M, Cauwels C, Sharpless NE, Wong WH, Chin L,. 2003. Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. Cancer Res 63 (17): 5352-5356.
66. Pandey V, Vijayakumar MV, Ajay AK, Malvi P, Bhat MK,. 2012. Diet-induced obesity increases melanoma progression: involvement of Cav-1 and FASN. Int J Cancer 130 (3): 497-508.
67. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS,. 2011. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71 (7): 2750-60.
68. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M,. 2010. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140 (2): 197-208.
69. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI,. 2005. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15 (3): 249-254.
70. Paz-Filho G, im EL, Wong ML, Licinio J,. 2011a. Associations between adipokines and obesity-related cancer. Front Biosci 16: 1634-1650.
71. Paz-Filho G, Wong ML, Licinio J,. 2011b. Ten years of leptin replacement therapy. Obes Rev 12 (5): e315-e323.
72. Pin JP, Gomeza J, Joly C, Bockaert J,. 1995. The metabotropic glutamate receptors: Their second intracellular loop plays a critical role in the G-protein coupling specificity. Biochem Soc Trans 23 (1): 91-96.
73. Pollak M,. 2012. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12 (3): 159-169.
74. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS,. 2003. High frequency of BRAF mutations in nevi. Nat Genet 33 (1): 19-20.
75. Populo H, Soares P, Lopes JM,. 2012. Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert opinion on therapeutic targets 16 (7): 689-705.
76. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, Leboit PE, Ortiz-Urda S,. 2013. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Nat Acad Sci USA.
77. Prickett TD, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y,. 2009. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41 (10): 1127-1132.
78. Rakosy Z, Vizkeleti L, Ecsedi S, Voko Z, Begany A, Barok M, Krekk Z, Gallai M, Szentirmay Z, Adany R, Balazs M,. 2007. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 121 (8): 1729-1737.
79. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M,. 2008. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371 (9612): 569-578.
80. Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris DA, Shellman YG,. 2006. RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J Invest Dermatol 126 (4): 862-868.
81. Rzeski W, Turski L, Ikonomidou C,. 2001. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98 (11): 6372-6377.
82. Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr., 2004. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15 (1): 35-43.
83. Sensi M, Petti NG, Bersani C, Lozupone I, Molla F, Vegetti A, Nonaka C, Mortarini D, Parmiani R, Fais G, Anichini S, A,. 2006. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25 (24): 3357-3364.
84. Sharma D, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP,. 2010. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 52 (5): 1713-1722.
85. Sharma SD, Katiyar SK,. 2010. Leptin deficiency-induced obesity exacerbates ultraviolet B radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet B-irradiated mouse skin. Toxicol Appl Pharmacol 244 (3): 328-335.
86. Sharma A, Zimmerman TN, Tuveson MA, Smith DA, Robertson CD, GP,. 2005. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65 (6): 2412-2421.
87. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L,. 2003. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 22 (32): 5055-5059.
88. Sharpless E, Chin L,. 2003. The INK4a/ARF locus and melanoma. Oncogene 22 (20): 3092-3098.
89. Shipman AR, M.G,. 2011. Obesity and the skin. Br J Dermatol. 165 (4): 743-750.
90. Smalley KS,. 2010. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol. 130 (1): 28-37.
91. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP,. 2004. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64 (19): 7002-7010.
92. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Buhrer C, Hansen HH, Stryjecka-Zimmer M, Turski L, Ikonomidou C,. 2005. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 102 (43): 15605-15610.
93. Stepulak A, Sifringer M, Rzeski W, Brocke K, Gratopp A, Pohl EE, Turski L, Ikonomidou C,. 2007. AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther 6 (12): 1908-1915.
94. Stepulak A, Luksch H, Uckermann O, Sifringer M, Rzeski W, Polberg K, Kupisz K, Klatka J, Kielbus M, Grabarska A, Marzahn J, Turski L, Ikonomidou C,. 2011. Glutamate receptors in laryngeal cancer cells. Anticancer Res 31 (2): 565-73.
95. Sumimoto H, Iwata IF, Kawakami T, Y,. 2006. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 203 (7): 1651-1656.
96. Suzuki S, Heldin CH, Heuchel RL,. 2007. Platelet-derived growth factor receptor-beta, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma. BMC Cancer 7: 224.
97. Sznol JA, Jilaveanu LB, Kluger HM,. 2012. Studies of NVP-BEZ235 in Melanoma. Cur Cancer Drug Targets.
98. Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M,. 2011. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther.
99. Thomas JA, Freedland SJ,. 2011. Obesity and prostate cancer: collateral damage in the battle of the bulge. Front Biosci (Schol Ed) 3: 594-605.
100. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S,. 2011. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Disease 2: e199.
101. Van Raamsdonk CD, Green BV, Bauer G, Gaugler J, O'Brien L, Simpson JM, Barsh EM, Bastian GS, BC,. 2009. Frequent somatic mutations of GNAQ in veal melanoma and blue naevi. Nature 457 (7229): 599-602.
102. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y,. 2011. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43 (5): 442-446.
103. Wurth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, Sirito R, Massollo M, Marini C, Zona G, Fenoglio D, Sambuceti G, Filaci G, Daga A, Barbieri F, Florio T,. 2013. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle 12 (1): 145-156.
104. Wysocki PJ, Wierusz-Wysocka B,. 2010. Obesity, hyperinsulinemia and breast cancer: Novel targets and a novel role for metformin. Expert review of molecular diagnostics 10 (4): 509-519.
105. Zhao L, V.P,. 2008. Class I PI3K in oncogenic cellular transformation. Oncogene. 27 (41): 5486-5496.
106. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC,. 2009. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33 (2): 237-247.